Cite

HARVARD Citation

    Kumar, A. et al. (2021). Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of clinical oncology. 39 (20), pp. 2257-2265. [Online]. 
  
Back to record